期刊
BIOMEDICINES
卷 10, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10051130
关键词
immune checkpoint blockade; TNBC; resistance
资金
- Hanyang University [HY-202100000003291]
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2021R1F1A1062411, 2022R1C1C1011387]
- National Research Foundation of Korea [2022R1C1C1011387, 2021R1F1A1062411] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Immune checkpoint blockades have greatly improved cancer treatment, but a significant number of TNBC patients do not respond to these therapies, and mechanisms of resistance are poorly understood. This review focuses on biomarkers and recent advances in understanding molecular mechanisms of resistance to ICBs in TNBC.
Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据